Carilizumab and chemo for advanced gastric cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of carilizumab (an immunotherapy) and albumin paclitaxel (a chemotherapy drug) for people with advanced stomach or gastroesophageal junction cancer that has gotten worse after first-line treatment. It aims to see if this second-line option can help control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 75 years old.
- You have advanced gastric or gastroesophageal junction adenocarcinoma that has progressed after one prior treatment.
- You have at least one measurable tumor that hasn't been treated with radiation recently.
- You are well enough to be up and about (ECOG score 0-1) and have adequate organ function.
- Your cancer is HER2 negative (a specific protein test).
- You have not had severe side effects from immunotherapy or prior treatment with paclitaxel drugs.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new chemotherapy combination for patients with advanced stomach cancer that has worsened after initial treatment. It aims to find a better second-line option using a drug called nab-paclitaxel.
This trial tests a combination of two drugs: carilizumab (an immunotherapy) and apatinib (a targeted therapy) for patients with unresectable stage III or IV gastric cancer that has a specific DNA repair problem (dMMR). The goal is to see if this treatment can help shrink tumors and improve outcomes.
This trial tests a combination of low-dose radiation, chemotherapy, and an immunotherapy drug (AK112) for people with advanced stomach or gastroesophageal junction cancer that has progressed after first-line treatment. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
This trial tests a combination of three drugs—adebrelimab (an immunotherapy), fruquintinib (a targeted therapy to cut off blood supply to the tumor), and a chemotherapy (paclitaxel or albumin-bound paclitaxel)—in people with advanced stomach/gastric cancer whose disease has worsened after one prior chemotherapy. The goal is to see if this new mix can help control the cancer.
This trial tests a drug called camrelizumab, alone or with other treatments, for people with advanced stomach cancer that has worsened or returned. It aims to see how well this treatment works in real-world patients.
This trial tests a combination of three drugs (adebrelimab, apatinib, and paclitaxel) for people with advanced stomach or gastroesophageal junction cancer that has progressed after immunotherapy. The goal is to see if this combination helps control the cancer longer.
Hear when a new Gastric Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.